Skip to content 
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany. more
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | |||
|---|---|---|---|---|---|---|
| Total Revenue | 577.35K | 529.88K | 895.48K | 893.99K | [{"date":"2021-12-31","value":64.47,"profit":true},{"date":"2022-12-31","value":59.17,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":99.83,"profit":true}] | |
| Cost of Revenue | 399.73K | 347.73K | 385.82K | 319.11K | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":86.99,"profit":true},{"date":"2023-12-31","value":96.52,"profit":true},{"date":"2024-12-31","value":79.83,"profit":true}] | |
| Gross Profit | 177.62K | 182.15K | 509.66K | 574.88K | [{"date":"2021-12-31","value":30.9,"profit":true},{"date":"2022-12-31","value":31.68,"profit":true},{"date":"2023-12-31","value":88.65,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] | |
| Gross Margin | 30.77% | 34.38% | 56.91% | 64.31% | [{"date":"2021-12-31","value":47.84,"profit":true},{"date":"2022-12-31","value":53.46,"profit":true},{"date":"2023-12-31","value":88.51,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] | |
| Operating Expenses | 9.90M | 26.63M | 27.15M | 19.27M | [{"date":"2021-12-31","value":36.47,"profit":true},{"date":"2022-12-31","value":98.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":70.97,"profit":true}] | |
| Operating Income | (9.72M) | (26.44M) | (26.64M) | (18.70M) | [{"date":"2021-12-31","value":-972460600,"profit":false},{"date":"2022-12-31","value":-2644404000,"profit":false},{"date":"2023-12-31","value":-2664468200,"profit":false},{"date":"2024-12-31","value":-1869540800,"profit":false}] | |
| Total Non-Operating Income/Expense | (2.30M) | (232.62K) | (460.63K) | (4.03M) | [{"date":"2021-12-31","value":-230466300,"profit":false},{"date":"2022-12-31","value":-23262000,"profit":false},{"date":"2023-12-31","value":-46062600,"profit":false},{"date":"2024-12-31","value":-403048700,"profit":false}] | |
| Pre-Tax Income | (11.69M) | (26.39M) | (26.30M) | (21.65M) | [{"date":"2021-12-31","value":-1169009800,"profit":false},{"date":"2022-12-31","value":-2638733600,"profit":false},{"date":"2023-12-31","value":-2629572700,"profit":false},{"date":"2024-12-31","value":-2165066300,"profit":false}] | |
| Income Taxes | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |
| Income After Taxes | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |
| Income From Continuous Operations | (11.69M) | (26.39M) | (26.30M) | (21.65M) | [{"date":"2021-12-31","value":-1169009800,"profit":false},{"date":"2022-12-31","value":-2638733600,"profit":false},{"date":"2023-12-31","value":-2629572700,"profit":false},{"date":"2024-12-31","value":-2165066300,"profit":false}] | |
| Income From Discontinued Operations | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |
| Net Income | (11.69M) | (26.39M) | (26.30M) | (21.65M) | [{"date":"2021-12-31","value":-1169009800,"profit":false},{"date":"2022-12-31","value":-2638733600,"profit":false},{"date":"2023-12-31","value":-2629572700,"profit":false},{"date":"2024-12-31","value":-2165066300,"profit":false}] | |
| EPS (Diluted) | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |
These ratios help you determine the liquidity of the company. Higher is better.
| QUCY | |
|---|---|
| Cash Ratio | 0.32 |
| Current Ratio | 0.52 |
| Quick Ratio | 0.43 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| QUCY | |
|---|---|
| ROA (LTM) | 0.00% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| QUCY | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.74 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.26 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| QUCY | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 8.34 |
| P/B | 2.49 |
| EV/R | 11.30 |
| EV/Ebitda | NM |
Mainz Biomed N.V. (QUCY) share price today is $0.4163
Yes, Indians can buy shares of Mainz Biomed N.V. (QUCY) on Vested. To buy
Yes, you can purchase fractional shares of Mainz Biomed N.V. (QUCY) via the Vested app. You can start investing in Mainz Biomed N.V. (QUCY) with a minimum investment of $1.
You can invest in shares of Mainz Biomed N.V. (QUCY) via Vested in three simple steps:
The 52-week high price of Mainz Biomed N.V. (QUCY) is $0.94. The 52-week low price of Mainz Biomed N.V. (QUCY) is $0.41.
The price-to-earnings (P/E) ratio of Mainz Biomed N.V. (QUCY) is
The price-to-book (P/B) ratio of Mainz Biomed N.V. (QUCY) is 2.49
The dividend yield of Mainz Biomed N.V. (QUCY) is 0.00%
The market capitalization of Mainz Biomed N.V. (QUCY) is $5.51M
The stock symbol (or ticker) of Mainz Biomed N.V. is QUCY
Consider the share price of Mainz Biomed N.V. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Mainz Biomed N.V. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Mainz Biomed N.V. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Mainz Biomed N.V. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Mainz Biomed N.V. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Mainz Biomed N.V. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
